NL-OMON36141已完成不适用
An Open Label, Non-Randomized, Single dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2251052 Administered as a Single Intravenous Dose to Healthy Adult Subjects (LRS115243) - [14C]-GSK2251052 mass balance study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects
- •Age: 30-55 years
- •BMI: 18.5-30.0 kg/m2
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1 liter of blood in the 10 months prior the start of this study.
研究者
相似试验
招募中
4 期
A study to understand if different brands of the drugs Erlotinib or Gefitinib used in lung cancer give the same concentration in blood of patients and whether they can be used interchangeably.CTRI/2017/09/009954DR REDDYS LABORATORIES LTD180
已完成
不适用
To evaluate bio availability study of comparing Vitamin D3 (cholecalciferol) Nano emulsion soft gel capsules in healthy, adult human subjects under fasting conditions.CTRI/2022/03/041135Amitojas Wellness Pvt Ltd36
尚未招募
不适用
Bioequivalence Study of Sulfadoxine/Pyrimethamine 500 mg/25 mg Dispersible Tablets in Healthy subjects.CTRI/2018/11/016376Rena Exports
已完成
1 期
A clinical trial study to determine the oral bioavailability of curcuminoid capsules.CTRI/2021/05/033903Pharmabase SA24
已完成
不适用
Bioequivalence study of Cladribine 10 mg tablet in highly active relapsing multiple sclerosis patientsCTRI/2021/09/036201Hikma Pharmaceuticals40